ZBH — Zimmer Biomet Holdings, Inc.

The market is giving ZBH credit for the beat-and-raise but not much more. Q2 2026 (reported Aug 5, 2026) delivered $2.177B revenue vs ~$2.135B consensus and adjusted EPS of $2.07 vs $2.01 expected, and FY26 organic growth guidance was lifted to 2.25%-3.25% with adjusted EPS to $8.47-$8.59. But critics correctly flag that adjusted EPS was flat year-over-year ($2.07 vs $2.07) and adjusted net earnings fell 2.8% ($399.6M), with per-share figures flattered by share-count reduction. Persistent headwinds — ~100bps annual pricing erosion, China volume-based procurement, Japan supply constraints, and sluggish International Knees (down 1.5% cc vs a strong Stryker) — keep the tone cautious. As of 2026-09-13 the tape reflects that: RSI 40.04, -5.2% vs SMA20, -4.49% over 1 month, and a Wall Street consensus rating of Hold (17 buy / 22 hold / 3 sell).

Revenue has climbed steadily from $1.754B in Q3 2023 to $2.177B in Q2 2026, but the growth rate is uneven and now softening. Reported YoY growth ran roughly +4% through mid-2024, accelerated to +7.0% (Q2 2025), +9.7% (Q3 2025), +10.9% (Q4 2025) and +9.3% (Q1 2026), then decelerated to +4.8% in Q2 2026 — a clear recent slowdown, and management's full-year organic guide of just 2.25%-3.25% implies reported figures have been flattered by FX/acquisitions and that underlying organic growth is only low-single-digit. Margins show no structural trend: operating margin has oscillated in a 12.8%-19.2% band across the last 12 quarters and sits at 15.0% in Q2 2026, with TTM operating margin of 15.7% and net margin of 9.5%. GAAP EPS is noisy ($0.70 in Q4 2025 to $1.22 in Q1 2026) and the Q2 2026 GAAP figure of $1.03 lags adjusted EPS of $2.07, so 'earnings growth' is largely buyback-driven, not operating. Free cash flow is the bright spot: consistently positive every quarter, ranging ~$130M to ~$526M, with roughly $1.27B generated over the trailing four quarters (Q3 2025-Q2 2026). Bottom line: stable but slow-growing revenue, flat/range-bound margins, and reliable cash generation — an inflection story that keeps getting deferred, not a structural collapse.

Cheap on cash-flow metrics, unremarkable on GAAP. TTM P/E is 22.6x ($4.198 EPS), but that is distorted by heavy amortization/restructuring; on adjusted/forward numbers the stock trades at roughly 11.0x next-FY consensus EPS of $8.53 (as of 2026-09-13, $93.49 / $8.53). That is a deep discount to med-tech peers (Stryker, Boston Scientific often 25x+) and to ZBH's own 5-year average P/E of 50.7x — though that average is skewed by depressed-earnings years, so the more honest comparison is the 5-year average P/S of 3.2x versus today's 2.13x. The PEG ratio of 93.3 is essentially meaningless given sub-5% earnings growth. P/B of 1.42x is low, dividend yield of 1.06% is modest, and the balance sheet is reasonable (D/E 0.59, current ratio 1.69, LT debt down to $6.28B from $6.94B in Q4 2025). Verdict: cheap versus its own history and versus peers, but the discount is a rational reflection of low organic growth (~2-3%), mid-teens operating margins that aren't expanding, and a 5.5% ROIC barely above cost of capital — not a mispricing the market has simply overlooked.

The market is pricing skepticism, not optimism: ~11x forward EPS for a company that just beat and raised. That means there is optionality if organic growth merely stabilizes in the 3-4% range and margins hold — a re-rating to 13-14x forward EPS would imply meaningfully higher prices. But the flip side is a value-trap setup: if China VBP, ~100bps pricing erosion, and International Knee share losses keep organic growth below ~3%, the low multiple simply stays low and investors earn only the ~7% FCF yield and buyback. Watch cash conversion rather than headline EPS — the accruals ratio of -1.09% (as of 2026-06-30) is healthy, meaning operating cash flow exceeds net income, so the wide GAAP-to-adjusted EPS gap ($4.20 TTM GAAP vs $8.53 forward adjusted) reflects real non-cash amortization rather than a red flag on earnings quality. The key tension: buybacks are shrinking the share count and lifting EPS while the operating business grows slowly — fine as long as you don't pay too much, which at ~11x you aren't.

Range-bound with a fresh short-term pullback. As of 2026-09-13, RSI stood at 40.04 — weak but not yet oversold; price was -5.2% below the 20-day SMA and -1.93% below the 50-day, but still +2.24% above the 200-day. Returns: -4.67% over 1 week, -4.49% over 1 month, +5.55% over 3 months, +0.31% over 6 months. The setup is a stock that rallied earlier in the year, has given back short-term gains, and is now leaning on the 200-day as support. Entry-timing implication: this is not a knife-catch (RSI 40, not <30) and not a breakout — a patient buyer could wait for stabilization (RSI turning up, or a reclaim of the 20/50-day) rather than buying into a falling short-term trend, while a longer-horizon value buyer would focus on the ~$79-$107 52-week range and the ~2.2% cushion over the 200-day.

• Aging global demographics — the durable structural tailwind for joint replacement and orthopedic procedure volumes.
• Medical-device pricing pressure and China volume-based procurement (VBP), a persistent ~100bps annual revenue headwind that caps margin expansion.
• Interest rates / cost of capital — ~$6.3B of long-term debt means refinancing costs and valuation multiples are rate-sensitive, though a low beta (0.47) makes ZBH a defensive, rate-friendly holding.
• FX and international exposure — reported revenue growth (e.g. +9.3% in Q1 2026) far exceeds the low-single-digit organic guide, implying meaningful currency/acquisition distortion and geographic supply constraints (Japan).
• Elective-procedure volumes and healthcare-budget cycles — resilient but not immune to consumer or payer pressure; sector rotation in and out of defensive med-tech affects the multiple.

• Q3 2026 earnings expected Nov 4, 2026 (consensus EPS ~$1.88) — the key read on whether organic growth is stabilizing after the Q2 deceleration.
• Multi-year pipeline: 50+ new products over 36 months, with ROSA Shoulder robotic adoption and digital-ecosystem integrations as the watch items.
• Expanded $1B share buyback — a direct EPS and per-share FCF tailwind as long as the multiple stays low.
• Completion of the U.S./international go-to-market salesforce transition (tracked ahead of schedule) with minimal disruption.
• Any easing of China VBP or International Knee share losses, which would support a multiple re-rating.

• Structural pricing erosion (~100bps/year) plus China VBP that keeps international growth anemic and margins range-bound.
• Competitive share loss — notably International Knees down 1.5% cc while rivals like Stryker grow, signaling a competitive-position problem, not just a macro one.
• Low returns on capital — ROIC of 5.5% and ROE of 5.6% are barely above cost of capital, meaning reinvested dollars create limited value.
• Leverage and capital allocation — ~$5.9B net debt (~3x EBITDA) and a buyback-heavy return strategy that flatters EPS while the operating business grows slowly.
• Execution risk on the commercial restructuring and supply constraints (Japan), plus a wide GAAP-to-adjusted EPS gap ($4.20 vs $8.53) that can mask underlying softness if investors focus only on headline guidance.

ZBH is a cheap, cash-generative, defensive med-tech name with a growth problem, not a broken business. At ~11x forward EPS, a ~7% FCF yield (~$1.27B trailing FCF on an $18.1B market cap), a 1.06% dividend, a low beta, and a solid balance sheet (current ratio 1.69, D/E 0.59), the downside looks cushioned for a company whose demographic demand is intact. But organic growth is decelerating (guide 2.25%-3.25%), operating margins are stuck in the mid-teens, ROIC is only 5.5%, and management is defending International Knees against Stryker. This is 'value with a ceiling' — worth holding for income and optionality on a re-rating, but not a high-conviction buy until organic growth or margins show a genuine inflection. As of 2026-09-13 the risk/reward is mildly favorable but not compelling.

Blended forward-P/E and FCF-yield approach, run as of 2026-09-13. Primary: ~12.5x next-FY consensus EPS of $8.53 (a discount to slow-growth med-tech peers like Medtronic at ~17x, reflecting ZBH's 2-3% organic growth and mid-teens margins) implies $106.6. Cross-check: TTM FCF of ~$1.27B over ~193.5M shares gives ~$6.58 FCF/share; at a 6.2% required FCF yield that is ~$106. Both methods converge near $106, roughly 13% above the $93.49 price and modestly above the $103-104 consensus target.